Pfizer bags rheumatoid arthritis rights to new immunotherapy class through deal with Imcyse

Pfizer has teamed up with Imcyse to develop treatments for rheumatoid arthritis. The agreement will give Pfizer the chance to access modified peptides designed to induce cytolytic T cells and thereby eliminate the disease pathway without affecting the rest of the immune system.